Telix Pharmaceuticals Limited is a clinical-stage biotechnology company dedicated to the development and commercialisation of advanced theranostic (therapeutic + diagnostic) oncology products. Our products seek to address major clinical unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.

We offer better-informed treatment decisions and truly personalised therapy through radiopharmaceuticals, which intrinsically enable superior diagnosis (imaging) and therapy of cancer.

Our product development strategy is to closely integrate and add value to standard care, reflective of the modern team-based approach to managing cancer in a clinical setting. Our mission is to help patients with cancer live longer with better quality lives.